Doxazosin Tablet
Product Images NDC 70518-3667

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 70518-3667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Doxazosin 2mg 70518 3667 00)

Mm1 (Doxazosin 2mg 70518 3667 00)
This is a description of a medication, specifically Doxazosin with a strength of 2mg. It comes in a bottle of 30 tablets, with an NDC number of 70518-3667-00 and a LOT number to be filled in. The medication is manufactured by Apotex Corp in Weston, FL with a source NDC of 60505-0094-00. The recommended storage temperature is 20-25°C (88-77°F) with excursions permitted up to 15-30°C (59-86°F). The medication should be kept out of the reach of children. The direction for use is to refer to the package insert. The medication has been repackaged by RemedyRepack Inc. located in Indiana, PA with contact number 724.465.8762.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

FDA Label Image

Figure1.jpg (Figure1)

FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
This is a summary of effectiveness data obtained from placebo-controlled trials for the treatment of benign prostatic hyperplasia (BPH), a condition where the prostate gland enlarges and causes difficulty in urination. The studies evaluated the maximum urinary flow rate and symptom scores of patients before and after the use of doxazosin, a medication used to relax the muscles in the prostate and bladder neck, and placebo. The results showed that patients treated with doxazosin had a greater improvement in urinary flow rate and symptom scores compared to those treated with placebo. The studies had different dosing regimens, namely titration to maximum dose, fixed dose for 14 weeks, and fixed dose for 12 weeks. The results were measured using the AUA questionnaire and the Modified Boyarsky questionnaire.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.